Navigation Links
Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
Date:9/22/2008

Ernst & Young Releases its inaugural 2008 US Medtech Report

WASHINGTON, Sept. 22 /PRNewswire/ -- Private investment in the US medical technology industry has remained strong over the past 18 months, despite a precipitous drop in public equity funding this year due to the global credit crunch. At the same time, the 301 US-headquartered, publicly traded medical technology companies produced solid growth in revenues and earnings, driven by continued innovation and heightened demand brought by emerging medical and demographic trends. These and other findings are highlighted in Pulse of the industry: US medical technology report 2008, Ernst & Young LLP's first-ever report on the industry's performance, released today at the AdvaMed 2008 Medical Technology conference in Washington, D.C.

"While the credit crunch has depressed public equity financing, venture capital and deal activity remain solid," said Richard Ramko, Ernst & Young's US Medical Technology Leader. "The industry is poised for growth in the years ahead due to aging populations, the wider prevalence of chronic diseases, and an expected surge in demand for companion diagnostics to accompany new generations of targeted therapies."

Key industry findings described in the report include:

-- Financing. The US medtech industry had its second consecutive strong financing year in 2007, led by solid investment on the venture capital (VC) and public equity fronts. US companies raised nearly US$10.7 billion, a 2% increase over 2006 and a 165% increase over capital raised in 2005. However, in the first half of 2008, capital raised by the industry fell to $3.2 billion, largely because of declining funding from public investors.

-- Venture capital. Medtech companies attracted record amounts of venture capital in 2007 and sustained that pace in the first half of 2008. Total VC funding reached US$3.7 billion in 2007, a 37% increase over the previous record-setting year of 2006. Thr
'/>"/>

SOURCE Ernst & Young LLP
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts
2. Gen-Probe to Webcast Presentation at the Bank of America 38th Annual Investment Conference
3. Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment
4. Abbott to Present at UBS Best of Americas Investment Conference
5. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
6. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
8. The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future
9. Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments?
10. Investment Firm Allied Minds to Commercialize New Frozen Aliquotter Technology with Two Local Major Universities.
11. Delaware Valley Innovation Network Awards First Innovation Investment Grant to the Wistar Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce ... , an e-Journal and producer of Food Labs ... year for the co-location of Food Labs Conference to be ... the registration fee to attend the two-day Food Lab Conference, ...
(Date:1/15/2014)... Look inside the new Preferred Solutions® ... lab, from fluid handling to instruments to supplies. Many ... you order. , Preferred Solutions features a full ... L/S® model for precise flow control and dispensing to ...
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... everyone has heard of identity theft (IDT), yet unless you ... at high risk. An alarming figure is that over half ... a place of business, employer, or other entity (not-for-profit or ... individuals are required under one or more federal and state ...
... American angel investors continue to be the largest source of ... in the first half of 2006, an increase of 15 ... Center for Venture Research at the University of New ... research on the angel market since 1980, reported that healthcare ...
... had a crystal ball that could help him predict the ... president and research fellow at Yahoo , has a ... called "the cash cow with a big target on it." ... user-generated content (combined with search) that will somehow enable professionals ...
Cached Biology Technology:Identity theft: The business time bomb 2Identity theft: The business time bomb 3Identity theft: The business time bomb 4Angel investors commit $12.7B in first half of `06 2Online communities may be next business market 2Online communities may be next business market 3
(Date:7/9/2014)... cooks are turning to more healthful alternatives to their ... sometimes mean low satisfaction. Now researchers are reporting new ... that are made with olive oil rather than pork ... of Agricultural and Food Chemistry . , Ana M. ... to expect just the right amount of chewiness and ...
(Date:7/9/2014)... sparrow-sized fossil from China challenges the commonly held belief ... the ability to fly. The birdlike fossil is actually ... the remains of a tiny tree-climbing animal that could ... Museum in Blanding, Utah, and Alan Feduccia of the ... Journal of Ornithology . , The fossil of ...
(Date:7/9/2014)... developed by researchers at the NIH,s National ... its collaborators to treat sickle cell disease ... business. The drug candidate, Aes-103, is the ... molecular mechanism of sickle cell disease. Baxter ... required for regulatory approval and commercialization. , ...
Breaking Biology News(10 mins):Researchers declassify dinosaurs as being the great-great-grandparents of birds 2First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... Elsevier, a world-leading provider of scientific, technical and ... a new, international, open access journal, Case Studies ... Studies in Engineering Failure Analysis provides a forum ... Studies in Engineering Failure Analysis and will form ...
... of several of the most external atomic layers of ... Analysis by a number of modern techniques. Just opened ... Academy of Sciences, Warsaw, Poland, the Centre provides a ... electron microscope and specialised spectroscopic equipment for surface studies ...
... PHOENIX, Nov. 26, 2012 Webcast AdvisoryWhat:Announcement of a ... internationally respected team racing to unlock genomic codes ... lead to biomedical breakthroughs that will give new ... diagnoses.Who:Phoenix Children,s Hospital, in collaboration with Translational Genomics ...
Cached Biology News:Elsevier launches new open access journal -- 'Case Studies in Engineering Failure Analysis' 2Surface analysis techniques for advanced materials enhance Mazovia's research potential 2Surface analysis techniques for advanced materials enhance Mazovia's research potential 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
Biology Products: